TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03625284

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Edible oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FucoVital
Description: Microalgae oil extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FucoVital
Description: Microalgae oil extract
Study: NCT03334032

Intervention type: OTHER
Intervention: Inpatient treatment for Anorexia nervosa
Description: Nutritional rehabilitation in a clinic with specialized eating disorder service
Study: NCT02610582

Intervention type: DRUG
Group type: OTHER
Intervention: rAAV.hCNGA3
Description: Single subretinal injection of rAAV.hCNGA3

Intervention type: DRUG
Group type: OTHER
Intervention: rAAV.hCNGA3
Description: Single subretinal injection of rAAV.hCNGA3
Study: NCT02849119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or robotic partial nephrectomy
Description: Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or robotic partial nephrectomy
Description: Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
Study: NCT02197702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
Study: NCT00855816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: relaxation training
Study: NCT02177188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBNP Lower Bodi Negative Pressure Chamber
Study: NCT01858363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare Percutaneous Transluminal Angioplasty Balloon Catheter
Study: NCT04004910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma soluble TNF receptor pulldown
Description: The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
Study: NCT03962803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Description: three-dose, 20 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 20 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 60 µg per dose
Study: NCT00075335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100 (Mozobil plerixafor)
Description: AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
Study: NCT05286190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bupivacaine 0.25% Injectable Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bupivacaine 0.25% Injectable Solution
Study: NCT03618264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miscible liquid of dexamethasone and ropivacaine
Description: Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT04004910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma soluble TNF receptor pulldown + chemotherapy
Description: The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect.
Study: NCT03618264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT04004910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Drugs, Cancer
Description: Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
Study: NCT04526912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Single subcutaneous dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous single dose matched to VIB7734.
Study: NCT02837458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency
Description: high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT03174366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
Study: NCT01255891

Intervention type: RADIATION
Group type: OTHER
Intervention: Androgen suppression plus radiation therapy
Description: Adjuvant androgen suppression plus radiation therapy
Study: NCT02636205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo therapy
Description: Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
Study: NCT04142801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeMo web application
Description: The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: the patient have the classical follow up at the memory center (consultation)
Study: NCT02016651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right side position
Description: Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
Study: NCT03992352

Intervention type: DIAGNOSTIC_TEST
Intervention: Age 60+ with planned HCT for Hematologic Malignancy
Description: questionnaires, geriatric assessments
Study: NCT04354662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m², d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1
Study: NCT01004926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echelon foot
Description: One Echelon foot for each subject, for a period of a month.
Study: NCT01753635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway placement and use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway placement and use
Study: NCT01458535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets
Study: NCT04098341

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection
Description: All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
Study: NCT02508623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550 mg tablet BID for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID for 60 days
Study: NCT02883972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Behavioural-insight informed letter template

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Behavioural-insight informed letter template

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control letter
Description: Invitation letter used by local area last year (updated as required)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control letter
Description: Invitation letter used by local area last year (updated as required)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Behavioural-insight informed SMS/email reminder message to return consent form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Behavioural-insight informed SMS/email reminder message to return consent form
Study: NCT01894087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBI - Cohort 1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBI - Cohort 2
Study: NCT02620995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
Study: NCT01458535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets
Study: NCT01687296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate inhalation solution
Description: 2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral prednisone
Description: once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo inhalation solution
Description: 4ml 0.9% saline nebulized twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: placebo soluble tablet, oral ,once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
Study: NCT01865227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Counseling
Study: NCT04041934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
Study: NCT01201720

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasma exchange with albumin
Description: Realization of 6 plasma exchange with albumin in 11 days
Study: NCT00673582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg/day rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 10 mg a day for 96 weeks
Study: NCT02891395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate and Nilotinib
Description: For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52.
Study: NCT02018081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 8 blood sampling by patients between the 48th and 60th
Study: NCT02478463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir tablet 30 mg once daily for 28 days.
Description: GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
Description: Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
Study: NCT02620995

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: comparator group
Description: Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
Study: NCT04848155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: socially assistive robot
Description: The intervention group will work with the ReMIND-system. This ReMIND-system consists of:~1. An existing socially assistive robot called James® that will be adapted based on the needs of the older adults and the robot's own functionality. For example, exercise videos and games to stimulate physical and cognitive activity will be developed and made available on the robot. The robot has to be programmed by the researcher using the ZBOS Control© application on a separate tablet that is connected to the robot.~2. The Keosity-app, an application specifically designed to support people in telling, documenting and sharing their life stories with others. This application will be available on the robot.
Study: NCT01458535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets
Study: NCT00993538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Study: NCT05206760

Intervention type: PROCEDURE
Intervention: Brain biopsy
Description: Biopsy of brain tissue
Study: NCT04577378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole
Description: After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)
Description: Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study: NCT01054456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonesetron
Description: One dose administered intravenously 30 minutes pre-chemotherapy
Study: NCT01688375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
Study: NCT01458535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules
Study: NCT00756431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Fracture reduction Screw without HA Coating (Hiploc)
Description: Hip Fracture reduction Screw without HA Coating (Hiploc)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Fracture reduction Screw with HA Coating (Hiploc)
Description: Hip Fracture reduction Screw with HA Coating (Hiploc)
Study: NCT02558855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thrust Joint Manipulation of the Lumbar Spine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-thrust Joint Manipulation of the Lumbar Spine
Study: NCT02509923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 10mg
Description: Z-215 10mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 10mg
Description: Rabeprazole Sodium 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 10mg
Description: Rabeprazole Sodium 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Rabeprazole Sodium 20mg tablets
Study: NCT03918421

Intervention type: OTHER
Intervention: Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)
Description: Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
Study: NCT01292187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcitonin at dinnertime
Description: Oral calcitonin at dinnertime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo at dinnertime
Description: Oral placebo at dinnertime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcitonin at bedtime
Description: Oral calcitonin at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo at bedtime
Description: Oral placebo at bedtime